Geron Corp

Cell-based therapies are emerging as a transformative approach in healthcare, with the global cell therapy market expected to grow from $4.7 billion in 2023 to over $20 billion by 2030. Several biotech companies announced significant milestones: Avaí Bio and Austrianova completed a Master Cell Bank for α-Klotho anti-aging therapy; Geron present...

Geron Corporation announced it will release its first quarter 2026 financial results on May 6, 2026, followed by a conference call and webcast at 8:00 a.m. Eastern Time. The commercial-stage biopharmaceutical company continues to advance its telomerase inhibitor RYTELO® (imetelstat), which is approved in the U.S. and EU for treating lower-risk m...

Geron Corporation announced the appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary. Williams brings extensive biopharmaceutical industry experience from previous roles at Vanda Pharmaceuticals, AgNovos Bioscience, and Stryker Corporation. The appointment is part of recent leadership strengthen...

Geron Corporation announced that its management team will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026. The commercial-stage biopharmaceutical company, which markets RYTELO® (imetelstat) for treating lower-risk myelodysplastic syndromes, continues to conduct pivotal Phase 3 trials in J...

Geron Corporation reported full year 2025 RYTELO net product revenue of $184 million with Q4 revenue of $48 million. The company ended 2025 with $401 million in cash and expects 2026 RYTELO revenue between $220-240 million. Operating expenses totaled $255 million in 2025, within guidance. Geron implemented a workforce reduction of approximately o...